81 related articles for article (PubMed ID: 19345417)
21. Overexpression of the novel oncogene SALL4 and activation of the Wnt/beta-catenin pathway in myelodysplastic syndromes.
Shuai X; Zhou D; Shen T; Wu Y; Zhang J; Wang X; Li Q
Cancer Genet Cytogenet; 2009 Oct; 194(2):119-24. PubMed ID: 19781444
[TBL] [Abstract][Full Text] [Related]
22. Human interferon regulatory factor-1 gene and its promoter sequences revealed by population-based complete gene sequencing.
Ji H; Ball TB; Liang BB; Kimani J; Plummer FA
DNA Seq; 2008 Jun; 19(3):326-31. PubMed ID: 17852336
[TBL] [Abstract][Full Text] [Related]
23. Aberrant increase in the immature platelet fraction in patients with myelodysplastic syndrome: a marker of karyotypic abnormalities associated with poor prognosis.
Sugimori N; Kondo Y; Shibayama M; Omote M; Takami A; Sugimori C; Ishiyama K; Yamazaki H; Nakao S
Eur J Haematol; 2009 Jan; 82(1):54-60. PubMed ID: 18801060
[TBL] [Abstract][Full Text] [Related]
24. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.
Neukirchen J; Blum S; Kuendgen A; Strupp C; Aivado M; Haas R; Aul C; Gattermann N; Germing U
Eur J Haematol; 2009 Nov; 83(5):477-82. PubMed ID: 19548919
[TBL] [Abstract][Full Text] [Related]
25. Relation between IRF-1 gene and acute myelocytic leukemia in Kashmiri population.
Khan T; Ganai BA; Masood A; Samoon J; Beigh SR; Qazi F
Asian Pac J Cancer Prev; 2011; 12(4):1035-9. PubMed ID: 21790247
[TBL] [Abstract][Full Text] [Related]
26. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
[TBL] [Abstract][Full Text] [Related]
27. IRF-9/STAT2 [corrected] functional interaction drives retinoic acid-induced gene G expression independently of STAT1.
Lou YJ; Pan XR; Jia PM; Li D; Xiao S; Zhang ZL; Chen SJ; Chen Z; Tong JH
Cancer Res; 2009 Apr; 69(8):3673-80. PubMed ID: 19351818
[TBL] [Abstract][Full Text] [Related]
28. Usefulness of immature platelet fraction for the clinical evaluation of myelodysplastic syndromes.
Saigo K; Takenokuchi M; Imai J; Numata K; Isono S; Zenibayashi M; Tanioka H; Yoshioka T; Nishizawa A; Takada M; Nomura T; Kubota Y
Lab Hematol; 2009; 15(2):13-6. PubMed ID: 19561008
[TBL] [Abstract][Full Text] [Related]
29. Low erythropoietin production as non-oncogenic co-factor contributing to disease-manifestation in low-risk MDS: a hypothesis supported by unique case reports.
Valent P
Leuk Res; 2008 Sep; 32(9):1333-7. PubMed ID: 18417212
[TBL] [Abstract][Full Text] [Related]
30. [Peculiarities of cytogenetic changes in different types of myelodysplastic syndrome].
Lozyns'ka MP; Vyhovs'ka IaI; Tomashevs'ka NIa; Masliak ZV; Lozyns'kyĭ RIu; Novak VL
Tsitol Genet; 2009; 43(1):61-8. PubMed ID: 19663317
[TBL] [Abstract][Full Text] [Related]
31. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.
Balleisen S; Kuendgen A; Hildebrandt B; Haas R; Germing U
Leuk Res; 2009 Sep; 33(9):1189-93. PubMed ID: 19428106
[TBL] [Abstract][Full Text] [Related]
32. Modulation of the early immune response against viruses by a teleostean interferon regulatory factor-1 (IRF-1).
Caipang CM; Hirono I; Aoki T
Comp Biochem Physiol A Mol Integr Physiol; 2009 Mar; 152(3):440-6. PubMed ID: 19101646
[TBL] [Abstract][Full Text] [Related]
33. Accelerated cellular senescence in myelodysplastic syndrome.
Wang YY; Cen JN; He J; Shen HJ; Liu DD; Yao L; Qi XF; Chen ZX
Exp Hematol; 2009 Nov; 37(11):1310-7. PubMed ID: 19748549
[TBL] [Abstract][Full Text] [Related]
34. Types I and II interferons upregulate the costimulatory CD80 molecule in monocytes via interferon regulatory factor-1.
Bauvois B; Nguyen J; Tang R; Billard C; Kolb JP
Biochem Pharmacol; 2009 Sep; 78(5):514-22. PubMed ID: 19433065
[TBL] [Abstract][Full Text] [Related]
35. Quality of life in myelodysplastic syndromes. A special report from the Myelodysplastic Syndromes Foundation, Inc.
Heptinstall K;
Oncology (Williston Park); 2008 Feb; 22(2 Suppl Nurse Ed):13-8; discussion 19. PubMed ID: 18434977
[TBL] [Abstract][Full Text] [Related]
36. Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts.
Cermak J; Kacirkova P; Mikulenkova D; Michalova K
Leuk Res; 2009 Nov; 33(11):1469-74. PubMed ID: 19646756
[TBL] [Abstract][Full Text] [Related]
37. Role of a distal enhancer in the transcriptional responsiveness of the human CD200 gene to interferon-gamma and tumor necrosis factor-alpha.
Chen Z; Marsden PA; Gorczynski RM
Mol Immunol; 2009 Jun; 46(10):1951-63. PubMed ID: 19386363
[TBL] [Abstract][Full Text] [Related]
38. Confirmation of differential binding of Interferon Regulatory Factor-1 (IRF-1) to the functional and HIV disease-influencing -2578 A/G polymorphism in CCL2.
Mummidi S; Bonello GB; Ahuja SK
Genes Immun; 2009 Mar; 10(2):197-8; author reply 199. PubMed ID: 18923432
[No Abstract] [Full Text] [Related]
39. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
Guan M; Chen SC; Ge CW
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
[TBL] [Abstract][Full Text] [Related]
40. Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes.
Pellagatti A; Marafioti T; Paterson JC; Malcovati L; Della Porta MG; Jädersten M; Pushkaran B; George TI; Arber DA; Killick S; Giagounidis A; Hellström-Lindberg E; Cazzola M; Wainscoat JS; Boultwood J
Br J Haematol; 2009 Jun; 146(1):86-90. PubMed ID: 19438482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
